Breast Cancer Protein 2: A Potential Drug Target Or Biomarker

Target Name: BLID

NCBI ID: G414899

BLID

Breast Cancer Protein 2: A Potential Drug Target Or Biomarker

Breast cancer is a leading cause of cancer-related deaths in women around the world. The development and progression of breast cancer is a complex process that involves the interplay of multiple factors, including genetic, hormonal, and environmental influences. One of the proteins that has been identified as a potential drug target or biomarker for breast cancer is called breast cancer cell protein 2 (BCP-2).

BCP-2 is a protein that is expressed in the cells of breast cancer tumors. It is a transmembrane protein that is involved in various cellular processes, including cell signaling, migration, and invasion. BCP-2 has been shown to play a role in the development and progression of breast cancer by promoting the growth and survival of cancer cells.

One of the key functions of BCP-2 is its role in cell signaling. BCP-2 is a negative regulator of the PI3K/Akt signaling pathway, which is a critical pathway that is involved in the regulation of cellular processes such as cell growth, differentiation, and survival. In cancer cells, the PI3K/Akt signaling pathway is often disrupted, leading to the uncontrolled growth and survival of cancer cells. By inhibiting the activity of this pathway, BCP-2 has been shown to be an effective drug target for breast cancer.

Another function of BCP-2 is its role in cell migration and invasion. BCP-2 has been shown to play a role in the migration and invasion of cancer cells. It is involved in the production of the protein PDGFR-尾, which is a critical factor in the development of cancer cell migration and invasion. In addition, BCP-2 has been shown to promote the formation of cancer cell-rich microenvironment, which can provide a survival advantage for cancer cells.

In addition to its role in cell signaling and migration, BCP-2 has also been shown to play a role in the regulation of cellular processes such as cell apoptosis, cell cycle progression, and cell growth. In cancer cells, the regulation of these processes is often disrupted, leading to the uncontrolled growth and survival of cancer cells. By promoting the regulation of these processes, BCP-2 has been shown to be an effective drug target for breast cancer.

As a potential drug target or biomarker, BCP-2 has the potential to be a valuable tool for the treatment of breast cancer. By inhibiting the activity of BCP-2, researchers may be able to reduce the growth and survival of cancer cells, leading to a more effective treatment of breast cancer. In addition, BCP-2 may also be a useful biomarker for the diagnosis and prognosis of breast cancer. By measuring the levels of BCP-2 in cancer cells, doctors may be able to determine the effectiveness of different treatments and monitor the progress of breast cancer.

In conclusion, BCP-2 is a protein that has been identified as a potential drug target or biomarker for breast cancer. Its role in cell signaling, migration, and invasion, as well as its role in the regulation of cellular processes such as apoptosis, cycle progression, and growth, make it an attractive target for cancer researchers. As more research is conducted on BCP-2, it is likely that its potential as a drug target or biomarker for breast cancer will be further confirmed.

Protein Name: BH3-like Motif Containing, Cell Death Inducer

Functions: Functions as a proapoptotic molecule through the caspase-dependent mitochondrial pathway of cell death

The "BLID Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BLID comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets